Women’s Health

  • Endometriosis
  • Hormonal contraception
  • Hormone replacement therapy
  • Infertility
  • Menorrhagia
  • Non-hormonal contraception
  • Postmenopausal osteoporosis
  • Uterine fibroids
  • Vulvovaginal atrophy

Aventine has completed dossiers, US-based economic models, and other medical communication tools for hormonal and non-hormonal women’s health products. Such products have included implantable devices and vaginal rings. Over the past decade, women’s health consensus statements and treatment guidelines have been greatly influenced by the long-term findings of the Women’s Health Initiative (WHI), and safety concerns arising from the WHI have affected many hormone-based products under development as well as in the active marketplace. Aventine team members have partnered with several pharma companies over the years to effectively navigate and develop appropriate value messages for products in this sensitive therapeutic arena.